ASH 2022 | FLT3-directed CAR-T vs FLT3-directed BiTE in preclinical AML model
Lisa Rohrbacher, PhD, Gene Center Munich, LMU Munich, Munich, Germany, describes the findings of a preclinical study comparing FLT3-directed CAR-Ts with a FLT3-directed bispecific T cell engager (BiTE) molecule in preclinical acute myeloid leukemia (AML) models. In vitro studies showed that both constructs induced comparable cytotoxicity and showed that the presence of CD38 increased BiTE-mediated lysis, and the addition of nivolumab and FLT3 inhibitors enhanced cytotoxicity in both constructs. In addition, in vivo studies showed that mice treated with FLT3-directed CAR-Ts had a longer overall survival (OS) than mice treated with FLT3-directed BiTEs. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
